This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Guirguis-Blake JM, Evans CV, Senger CA, Rowland MG, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No. 131. 2015

To systematically review evidence for the effectiveness of aspirin to prevent myocardial infarction (MI)/coronary events, stroke, cardiovascular death, and all-cause mortality in those without a history of cardiovascular disease (CVD). To review evidence for harms associated with aspirin use.

In primary prevention populations, aspirin modestly reduces nonfatal MI/coronary events and major CVD events, but also increases major GI bleeding risk. More precise realworld estimates for bleeding events, including major GI bleeding events and hemorrhagic stroke, are necessary to calculate the net benefit. At some absolute risk for 10-year CVD events, this absolute CVD benefit could potentially outweigh the bleeding risks. Models to identify these populations are needed.

Subject indexing assigned by CRD

Aspirin; Cardiovascular System; Humans; Primary Prevention

English

United States

An English language summary is available.

AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAP@ahrq.hhs.gov

32015001088

27/10/2015